Recently, a tumor-penetrating peptide, iRGD (CRGDKGPDC), was identified and reported to increase vascular and tissue penetration in a tumor-specific and neuropilin-1-dependent manner, as compared to conventional RGD peptides [13, 14]. The gene discussed is NRP1; the disease is neoplasm.